Leech Eicosanoid Modulator
Modulates prostaglandin and leukotriene cascades — anti-inflammatory pathway.
- Hementerin80 kDa
- Hementin80 kDa
- Hementin-Like Protein (HLP-1)80 kDa
- Leech Collagenase70 kDa
- Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
- Leech Apyrase67 kDa
- Calin65 kDa
- Hyaluronidase60 kDa
- Antithrombin III binding protein58 kDa
- Collagenolytic Fibrinolysin55 kDa
- Leech Thrombospondin-Like Protein50 kDa
- Leech Eicosanoid Modulator18 kDa
Mechanistic Evidence Box
Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.- Page type
- Compound profile
- Evidence type
- Preclinical / biochemical characterization
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Purified natural compound
Clinical translation limit
Leech eicosanoid-pathway modulation is mechanistic/hypothetical only and does NOT establish clinical anti-inflammatory efficacy. No FDA-approved derivative exists; distinct from FDA-approved cyclooxygenase or leukotriene-pathway drugs.
Molecular Profile
- Category
- Anti-inflammatory
- Evidence tier
- Preclinical
- Molecular weight
- 18,000 Da
- Source species
- Hirudo medicinalis
Biological Targets
- → cyclooxygenase, lipoxygenase pathways
External Resources
Related Anti-inflammatory Compounds
Leech C1 Inhibitor (LCi)
Complement system modulator targeting C1q activation — immunological homeostasis.
Leech Phospholipase A2 Inhibitor
Putative PLA2 inhibitor identified in leech salivary transcriptome — candidate eicosanoid-cascade modulator.
Haemadipsa yanyuanensis Progranulin (Hy-PGRN)
Putative progranulin gene with 122 cysteine residues and nine tandem repeats — distinctive structural organization (Lin 2025 chromosome-level genome).
WP-EAGSAKELEGDPVAG
Whitmania pigra-derived 15-residue anti-atherosclerosis peptide — Hu 2020 demonstrates inhibition of macrophage migration via JNK + p38 MAPK pathways.